文献速递免疫规划慢病防控与筛查

哮喘患者的重症COVID-19、疫苗接种与死亡率:全国性人群队列研究

Severe COVID-19, vaccination, and mortality among individuals with asthma: A Nationwide population-based cohort study.
PubMed 文献 · Vaccine · 2025-12-01

该研究基于韩国国民健康保险系统数据库,将哮喘患者按疫苗接种和感染状态分为四组,经1:1:1:1倾向评分匹配后纳入3384人。中位随访350天,未接种/感染组死亡率最高(3481/万人年),接种/未感染组最低(94/万人年)。COVID-19疫苗接种与哮喘患者长期死亡率降低相关,且不受感染状态影响。

要点

  • 哮喘患者中,未接种疫苗且感染COVID-19者死亡率最高。
  • 接种疫苗与哮喘患者长期死亡率降低相关,未感染时关联更强。
  • 重症COVID-19与哮喘患者死亡率显著升高相关。

核心结论

  • COVID-19疫苗接种与哮喘患者长期全因死亡率降低相关,无论其是否感染COVID-19。

研究设计与样本

  • 基于韩国国民健康保险系统数据库的全国性人群队列研究。
  • 哮喘患者按疫苗接种和COVID-19感染状态分为四组,经1:1:1:1倾向评分匹配后纳入3384人。
  • 主要结局为全因死亡率,采用两个多变量模型分析。

主要发现

  • 中位随访350天(四分位距294-407天),未接种/感染组死亡率最高(3481/万人年),接种/未感染组最低(94/万人年)。
  • 模型1中,以未接种/感染组为参照,接种/感染组死亡风险降低61%(HR 0.39,95%CI 0.31-0.50)。
  • 模型1中,未接种/未感染组HR 0.15(95%CI 0.10-0.21),接种/未感染组HR 0.04(95%CI 0.02-0.07)。
  • 模型2中,以未接种/未感染组为参照,接种/未感染组死亡风险降低74%(HR 0.26,95%CI 0.13-0.52)。
  • 模型2中,接种/感染组HR 2.69(95%CI 1.84-3.92),未接种/感染组HR 6.85(95%CI 4.86-9.67)。

临床怎么用

  • 应重视哮喘患者的COVID-19疫苗接种,以降低其长期死亡风险。
  • 对哮喘患者需加强重症COVID-19的预防和早期干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe coronavirus disease 2019 (COVID-19) often results in worse outcomes, including mortality, in individuals with asthma compared to those without the lung disease. However, it remains uncertain whether COVID-19 vaccination improves long-term mortality in individuals with asthma. METHODS: Using the Korean National Health Insurance System database, individuals with asthma were classified into four groups based on COVID-19 vaccination and COVID-19 infection status: vaccinated/uninfected, vaccinated/infected, unvaccinated/uninfected, and unvaccinated/infected individuals. After 1:1:1:1 propensity score matching, 3384 individuals with asthma were included. The primary outcome was all-cause mortality. Two multivariable models were employed: Model 1 used the unvaccinated/infected group as the reference, while Model 2 used the unvaccinated/uninfected group as the reference. RESULTS: Over a median follow-up duration of 350 days (interquartile ranges, 294-407 days), the mortality rate was highest in the unvaccinated/infected individuals (3481 per 10,000 person-years) and lowest in the vaccinated/uninfected individuals (94 per 10,000 person-years). In Model 1, among individuals with severe COVID-19, prior COVID-19 vaccination was associated with a 61 % reduction in mortality (hazard ratio [HR]: 0.39, 95 % confidence interval [CI]: 0.31-0.50). The risk of mortality was further decreased among uninfected individuals (HR: 0.15, 95 % CI: 0.10-0.21 for unvaccinated/uninfected individuals; HR: 0.04, 95 % CI: 0.02-0.07 for vaccinated/uninfected individuals). In Model 2, among uninfected individuals, COVID-19 vaccination exhibited a 74 % reduction in mortality risk (HR: 0.26; 95 % CI: 0.13-0.52), whereas individuals experiencing severe COVID-19 had markedly elevated mortality risks (HR: 2.69, 95 % CI: 1.84-3.92 for vaccinated/infected individuals and HR: 6.85, 95 % CI: 4.86-9.67 for unvaccinated/infected individuals). CONCLUSIONS: The COVID-19 vaccination was associated with reduced long-term mortality in individuals with asthma, regardless of COVID-19 status.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kim SH, Kang MG, Jang JG, et al. Severe COVID-19, vaccination, and mortality among individuals with asthma: A Nationwide population-based cohort study. Vaccine. 2025. PMID: 41330187. doi:10.1016/j.vaccine.2025.128017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。